MARKET IS CLOSED
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
CUE — Cue Biopharma, Inc.
NasdaqCue Biopharma, Inc.
$25.57
+0.32(+1.27%)
- O
- 25.60
- H
- 25.92
- L
- 24.67
- V
- 156.83K
⏱️ End-of-day dataAs of Oct 2, 2026
Chart
About CUE
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.
IndustryPHARMACEUTICAL PREPARATIONS
SectorNot available
IPO DateJan 2, 2018
Employees29
Stock ExchangeNasdaq
Ticker SymbolCUE
Websitehttps://www.cuebiopharma.com
Key Financial Statistics
| Market Cap | $185.75M |
| P/E Ratio | N/A |
| Dividend Yield | None |
| EPS | N/A |
| Beta | N/A |
| 52-Week Range | $4.98 - $45.50 |
| 52-Week Avg Volume | 276.2K |
| VWAP | $25.44 |
| Transactions | 3,196 |
| Total Recorded Bars | 2,200 days |